Slide 1: Exchange filing cover letter - Investor Presentation
Ref. No.: WOCK/SEC/SE/2025-26/013 5th June, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/ Madam, Sub
Slide 2: Investor Presentation June 2025
Investor Presentation June 2025
Slide 3: Disclaimer
Disclaimer This presentation contains “forward-looking statements” – that is, statements that relate to future, not past events or historical facts. All forward-looking statements are based on judgments derived from the information available to the company at this time. Forward-looking statements ca
Slide 4: Global Research-driven multinational
Global INR 3,033 Cr. FY25 Income Research - driven multinational INR 418 Cr. FY25 EBITDA Novel Antibiotics Biotechnology Pharmaceuticals 3
Slide 5: Global Footprint
Global Footprint FY25 sales contribution (%) 39% 12 manufacturing UK facilities across globe 23% India 2 R&D centers one each in India, UK 23% Emerging Markets 12% Ireland (& other EU) 4
Slide 6: Stronger business performance
Stronger business performance 67% 0.01 Y-o-Y EBITDA growth1 Net Debt : Equity ratio2 20% growth INR 326 Cr. for biosimilars in emerging markets3 Reduction in debt4 1. Growth in FY25 over FY24 2. As on 31st March 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (
Slide 7: Key positives for FY24-25: Development milestones
Key positives for FY24-25: Development milestones Successful completion of global Phase III cUTI study with 20% superiority ZAYNICH® Phase II Carbapenem-Resistant Organism study with >90% clinical efficacy (WCK 5222) NDA filed with DCGI, India Compassionate use: 51 lives saved MIQNAF® Appr
Slide 8: Key positives for FY24-25: QIP capital raise of INR 1,000 Cr.
Key positives for FY24-25 Sales Growth Operational Excellence Cost reductions & Achievements Emerging Markets 10% Manufacturing Re-structuring - External to Internal India Branded 4% Business Energy cost reduction initiative activated UK 8% Biotech New ~$30 Mn Wastage reduced from last year Business
Slide 9: Financial Highlight: 67% EBITDA growth
Financial Highlight: 67% EBITDA growth1 Total Income1 in INR Cr. EBITDA1 in INR Cr. 5% growth1 67% growth1 3,033 418 2,879 251 FY24 FY25 FY24 FY25 EBITDA Margin 9% 14% 8 1. FY25 vs FY24, excluding exchange rate fluctuations
Slide 10: Net Debt : Equity @ 0.01
Net Debt : Equity @ 0.011 Debt Reduction by INR 397 Cr.1 Equity INR Cr. Net Debt1 INR Cr. 4,202 4,657 3,662 3,662 975 882 461 64 As at 31st Mar'22 31st Mar'23 31st Mar'24 31st Mar'25 As at 31st Mar'22 31st Mar'23 31st Mar'24 31st Mar'25 Cash & Cash Equivalents and other Bank Balances INR Cr. Net Deb
Slide 11: Short-term and Mid-term growth drivers
Short-term and Mid-term growth drivers 3 years growth 5 years growth drivers drivers Glargine, Insulin Analogues, New Insulin Analogues, Diabetes Biosimilars for India + Emerging Human Insulin GLP-1 Analogues markets Zaynich® (WCK 5222), Foviscu® (WCK 4282), Miqnaf® (Nafithromycin), Odrate® (WCK 677
Slide 12: New Chemical Entity (Novel Antibiotics)
New Chemical Entity (Novel Antibiotics)
Slide 13: Drug Discovery team with more than 50 PhDs
Wockhardt drug discovery efforts focused on the antibiotics segment ~145 Drug Discovery team with more than 50 PhD’s. ~25 Focused commitment to Novel Antibiotics research leading to end-to- end Discovery & Development capabilities years Programs granted QIDP* status by US FDA denoting unmet needs; 6
Slide 14: Novel Antibiotics pipeline encompassing all the Resistant Organisms
Novel Antibiotics pipeline encompassing all the Resistant Organisms Gram Negative Portfolio Gram Positive Portfolio ZAYNICH® FOVISCU® ODRATE® EMROK® / MIQNAF® (WCK 5222) (WCK 4282) (WCK 6777) EMROK O® (Nafithromycin) Carbapenem resistant Phase I Global Phase III Launched in India; Phase III Complete
Slide 15: ZAYNICH (WCK 5222)
ZAYNICH® (WCK 5222) Establishing ꞵ-lactam enhancer - a new class of antibiotic to treat MDR/XDR Gram-negative infections
Slide 16: ZAYNICH: New class of antibiotic after >30 years
ZAYNICH® (WCK 5222): New class of antibiotic after >30 years to treat Gram-negative infections Global Phase III clinical study completed Global Phase III clinical study: achieved 20% higher (statistically superior) composite cure over gold standard Meropenem Phase II Carbapenem-Resistance Organism s
Slide 17: ZAYNICH (WCK 5222) Regulatory status
ZAYNICH® (WCK 5222) Regulatory status India: Filed to DCGI* Approval / launch expected in H2 FY25-26. US: Pre-NDA meeting completed with US FDA in May 2025 Filing to the US FDA in Q2 FY 25-26 with potential launch in FY26- 27 Europe & Emerging markets: Filing in H2 FY26 DCGI: Drug Controller General
Slide 18: Addressable pool of ~2 million patients for ZAYNICH
Addressable pool of ~2 million patients in select markets for ZAYNICH® (WCK 5222) Europe ~213Kc patients China ~657Ka patients USA ~158c patients India ~1,109Kb patients Excluding: Rest of World, Japan & Russia a) China : Adapted and derived using China incidence/epidemiology papers & CHINET China B
Slide 19: ~1.1 Million cases in India addressable by ZAYNICH
~1.1 Million cases in India addressable by ZAYNICH® (WCK 5222) for key indications Cases not treated Addressable Carbapenem Carbapenem Total cases* by newer cases for resistance % Resistance cases treatment ZaynichTM options ~2.2 -3.1 Mn ~1.4 -2.0 Mn ~1,109K Acinetobacter B. ~0.5-0.7 Mn 94% ~0.5-0.6
Slide 20: ZAYNICH addressable market in India ~INR 17K Crores
ZAYNICH® (WCK 5222) addressable market in India Total cases affected by Key Pathogens (E.coli, Klebsiella P., Pseudomonas A., Acinetobacter B) ~2.2 -3.1 Mn Carbapenem Resistance cases for key pathogens ~1.4 -2.0 Mn Carbapenem resistance cases not treated by newer therapy options and addressable by W
Slide 21: WCK 5222 addressable market of ~US$7 billion in USA and Europe
WCK 5222 addressable market opportunity of ~US$ 7 billion in USA and Europe Addresses major Gram-negative infections cUTI, HABP/VABP, BSI, cIAI, indications Pathogen coverage includes: Carbapenem resistant Acinetobacter B (CRAB), Carbapenem resistant Enterobacterales (CRE), Carbapenem resistant Pseu
Slide 22: MIQNAF (Nafithromycin)
MIQNAF® (Nafithromycin) Next generation respiratory tract infection antibiotic
Slide 23: Wockhardt has ended a >30 year wait for a new macrolide antibiotic
Wockhardt has ended a wait of > 30 years for a new antibiotic in Macrolide class with approval and launch of Miqnaf® (Nafithromycin) 22
Slide 24: MIQNAF: Broad spectrum novel lactone ketolide for CABP
MIQNAF® (Nafithromycin): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) & Upper Respiratory tract infections(RTI) Increasing resistance and incomplete coverage for current treatment options: − Macrolides (Azithromycin, Erythromycin) resistance in S. Pneumonia
Slide 25: MIQNAF outperforms current CABP first line treatment options
MIQNAF® (Nafithromycin) outperforms current CABP 1st line treatment options in terms of efficacy, treatment options and safety Macrolide Macrolide Penicillin Cephalosporin MIQNAF® Amoxicillin + Cefixime / Azithromycin Clarithromycin (Nafithromycin) Clavulanic acid Cefpodoxime Resistance (%) in S. Pn
Slide 26: MIQNAF: Addressable market in India
MIQNAF® (Nafithromycin): Addressable market in India RTI is one of the leading Rx category in India with ~367 Mn Rx 01 • • 62 Million Lower Respiratory Tract Infection Rx 305 Million Upper Respiratory Tract Infection Rx Antibiotics market size for Respiratory Tract Infection (RTI) in 02 India (at cu
Slide 27: Biotechnology
Biotechnology
Slide 28: Competitive advantage in Diabetes Biosimilars: Integrated capabilities
Competitive advantage in Diabetes Biosimilars: Integrated capabilities from lab to patient R&D Capabilities: Commercialization model 1 • Yeast, Bacterial & Mammalian expression India • Focused only on Diabetes segment - Insulin, Insulin Analogues • Product development, process development, analytica
Slide 29: Diabetes Biosimilars for Emerging markets - Competitive scenario
Diabetes Biosimilars for Emerging markets - Competitive scenario 1 Limited competition 6-7 players 2 Registered in emerging markets >30 markets Drug 3 Manufacturing infrastructure ready substance + Products Competitive Development 4 Integrated end to end capabilities scenario to marketing 5 Focus on
Slide 30: Significant opportunity opening up in Human Insulin
Significant opportunity opening up in Human Insulin due to changing market dynamics Change in market dynamics Novo Nordisk intends to discontinue its Human disposable insulin pens and cartridges. Initiative to increase production of GLP-1 analogues • Novo Nordisk's phase-out of Human Insulin cartrid
Slide 31: Comprehensive antidiabetic biosimilars pipeline
Comprehensive antidiabetic biosimilars pipeline across Human Insulin & Insulin analogs targeting India and Emerging Markets Commercialized Products 1 Recombinant Human Insulin 2 Glargine 100 IU Product Pipeline Aspart R Aspart 30/70 Lispro R Process development ✓ ✓ ✓ Process Scale Up ✓ ✓ ✓* Drug sub
Slide 32: Strategic growth levers
Strategic growth levers Robust Business performance driven by operational leverage Novel Antibiotic Portfolio : Best-in-class portfolio across infection spectrum targeting high value global markets Zaynich: A Breakthrough innovation Miqnaf: Oral Antibiotic for RTI − Life-saving innovation for gram n
Slide 33: Abbreviations
Abbreviations ®: Registered E.coli: Escherichia coli NCE: New chemical entity ~: Approximate EU: European Opinion NDA: New Drug Application A.baumannii: Acinetobacter baumannii Gram –ve: Gram negative NIH: National Institute of Health ABSSSI: Acute bacterial skin and skin Gram +ve: Gram positive PhD
Slide 34: Thank you
LiFE Focknaror \Yisks Thank you